In a hemodialysis patient with persistently elevated serum phosphorus despite calcium acetate therapy, normal serum calcium, and markedly increased intact parathyroid hormone, what is the likely cause, which non‑calcium phosphate binder and dose should be used, and is tenapanor an appropriate option for management?

Management of Refractory Hyperphosphatemia in Hemodialysis

You should immediately switch from calcium acetate to a non-calcium-based phosphate binder—specifically sevelamer 800-1600 mg three times daily with meals or lanthanum carbonate 500-1000 mg three times daily with meals—and consider adding tenapanor 30 mg twice daily as adjunctive therapy.

Root Cause Analysis

Your patient has severe secondary hyperparathyroidism (SHPT) driving persistent hyperphosphatemia despite maximal calcium-based binder therapy. The markedly elevated iPTH (>1100 pg/mL) is the primary driver here 1. High phosphate levels directly stimulate PTH secretion, creating a vicious cycle: hyperphosphatemia → increased PTH → further bone phosphate release → worsening hyperphosphatemia 1.

The current regimen is failing for three critical reasons:

• Calcium overload: 9 capsules/day of calcium acetate (667 mg each) delivers approximately 2.4 grams of elemental calcium daily—more than double the recommended safe limit 2
• Inadequate phosphate binding: Despite high-dose calcium acetate, phosphorus remains 10-12 mg/dL (target <5.5 mg/dL)
• Uncontrolled SHPT: The iPTH >1100 indicates the parathyroid glands are maximally stimulated, likely contributing to vascular calcification risk

Immediate Management Strategy

Step 1: Discontinue Calcium-Based Binders

Stop calcium acetate immediately. The 2017 KDIGO guidelines explicitly recommend restricting calcium-based binders in the presence of persistent hyperphosphatemia and elevated PTH 3. Your patient is at high risk for:

• Vascular calcification (Ca × P product = 93-113 mg²/dL², well above the target <55) 2
• Adynamic bone disease from calcium overload
• Progressive soft tissue calcification

Step 2: Initiate Non-Calcium Phosphate Binder

Choose either:

Sevelamer hydrochloride: Start 800 mg three times daily with meals, titrate up to 1600 mg three times daily as needed. Sevelamer is superior for your patient because:

• No systemic absorption or accumulation risk 4
• Most effective PTH reduction among non-calcium binders 5
• Reduces serum phosphate by approximately 2.1 mg/dL 5
• Lowers alkaline phosphatase more effectively (suggesting reduced bone turnover) 5

OR Lanthanum carbonate: Start 500 mg three times daily with meals, titrate to 1000 mg three times daily. Consider if:

• Cost is prohibitive for sevelamer
• Patient has significant GI intolerance to sevelamer
• Similar phosphate reduction (1.79 mg/dL) and alkaline phosphatase lowering 5

Step 3: Add Tenapanor as Adjunctive Therapy

Yes, tenapanor is an excellent option here. Start 30 mg twice daily (morning and evening, at least one hour before or two hours after meals).

Tenapanor is specifically FDA-approved for patients with inadequate response to phosphate binders 6, 7. Recent evidence shows:

• Reduces serum phosphate by 0.91-1.28 mg/dL when added to existing therapy 8
• Reduces iPTH by approximately 36.5 ng/L 8
• Improves bowel movements (49% of patients report this as primary benefit) 6—particularly valuable since phosphate binders cause constipation
• Reduces pill burden by 14% 6
• High adherence rate (94% prescription fill rate) 6

Key caveat: Tenapanor increases diarrhea risk 3.7-fold 8. Start conservatively and warn the patient. This side effect often improves with continued use 7.

Step 4: Optimize PTH Management

Your patient needs calcimimetic therapy urgently. The 2017 KDIGO guidelines recommend calcimimetics for dialysis patients requiring PTH-lowering therapy 3.

Add cinacalcet: Start 30 mg daily, titrate up to 90-180 mg daily based on PTH response. This will:

• Directly suppress PTH secretion
• Break the hyperphosphatemia-PTH cycle
• Allow phosphate binders to work more effectively

Continue doxercalciferol (Hectorol) 2 mcg IV with each HD for now, but monitor calcium closely. If hypercalcemia develops, reduce or hold temporarily 9.

Step 5: Discontinue Oral Vitamin D3

Stop the 1000 unit daily vitamin D3 supplement. You're already providing activated vitamin D (doxercalciferol) IV. Additional vitamin D supplementation increases calcium absorption and hypercalcemia risk 2.

Step 6: Dietary Counseling

Restrict dietary phosphate to 800-1000 mg/day while maintaining adequate protein (1.2 g/kg/day for HD patients). Focus on:

• Avoiding processed foods with phosphate additives (highly bioavailable)
• Limiting animal protein phosphate vs. plant-based sources 3, 9
• Educating about "hidden" phosphate sources

Monitoring Protocol

Week 1-2: Check calcium and phosphorus twice weekly 2 Week 3-4: Check calcium, phosphorus, iPTH weekly Month 2-3: Check monthly once stable

Target goals:

• Phosphorus: 3.5-5.5 mg/dL
• Calcium: 8.4-9.5 mg/dL
• Ca × P product: <55 mg²/dL²
• iPTH: 150-300 pg/mL (2-9× upper limit of normal for dialysis patients)

Critical Pitfalls to Avoid

1. Don't continue calcium acetate "because calcium is normal"—you're already at toxic calcium load levels with vascular calcification risk
2. Don't add tenapanor without warning about diarrhea—this is the most common reason for discontinuation
3. Don't delay calcimimetic therapy—iPTH >1100 will not respond to binders alone 10
4. Don't forget individual variability—dialytic phosphate removal varies by >400 mg per treatment between patients 10; if this regimen fails, consider more frequent or longer dialysis sessions

The combination of non-calcium binder + tenapanor + calcimimetic addresses all three mechanisms of hyperphosphatemia: intestinal absorption, dialytic removal inadequacy, and PTH-driven bone phosphate release.